Panasonic teams up with 7X Paralympic Champion Hannah Cockroft for Paris 2024 Paralympic Games
31.8.2023 18:31:00 EEST | Business Wire | Press release
Celebrating the countdown to the Paris 2024 Paralympic Games, Worldwide Olympic and Paralympic Partner Panasonic joins forces with the Team England wheelchair racing 7-time Paralympic Champion and 12-time World Champion, Hannah Cockroft to promote environmental sustainability on a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831059501/en/
Hannah Cockroft (Photo: Business Wire)
Since its founding, Panasonic has been committed to making positive contributions to the world and society. It has set ambitious targets to create a positive impact on environmental sustainability under its Panasonic GREEN IMPACT initiative. Hannah will join Team Panasonic as an ambassador focused on sustainability and inclusivity while receiving support from the company on her journey to her fourth Paralympic Games.
After picking up wheelchair racing at a talent day at Loughborough University in October 2007, Hannah has blazed a trail straight to legend status. As one of the most successful para-athletes in recent times, Hannah is looking forward to continuing to inspire people all over the world to embrace the Paralympic movement and celebrate inclusion.
Besides her tremendous athletic achievements, Hannah was one of 50+ Tokyo Olympians and Paralympians from 35 different countries, who took part in the Athletes of the World campaign which challenged World Leaders about the urgent need for ambitious climate action.
She is additionally using her platform to make a difference in issues beyond the sports arena, such as working with federations to reduce the use of single-use plastics. Panasonic is looking forward to working together with her on similar projects and initiatives that epitomise Panasonic’s core values of Contribution to Society, Cooperation & Team Spirit, and Untiring Effort & Improvement.
Hannah Cockroft comments, “It is a privilege to have Panasonic supporting me as I head into the Paris 2024 Paralympic Games. The backing and promotion to a wider audience will help me retain my top performing athlete position and enable me in turn to champion the need for climate change action, and increased inclusivity on a wider scale.”
Panasonic Champions the Champions
Panasonic has supported the Olympic and Paralympic Movements and their Athletes for nearly four decades. Several world-class athletes have been part of its Team Panasonic extended family. These athletes are committed to breaking barriers, improving communities, and bringing awareness to important issues such as sustainability, diversity, and inclusivity, and Hannah is no exception.
Junichi Suzuki, Chairman and CEO of Panasonic Europe B.V. comments, “Hannah’s focus on societal change, including being a patron and ambassador for several charities that enable her to encourage others to get active, alongside her participation in the sustainability initiatives, embodies the spirit of Team Panasonic.
We are proud to welcome her to the Team Panasonic family and have her be part of our team to shine a light on global climate change initiatives and innovations that tackle the world’s most pressing environmental problems.”
For more information about Panasonic GREEN IMPACT vision visit: https://www.panasonic.com/uk/corporate/sustainability.html
For more information about Panasonic as a Worldwide Olympic and Paralympic Partner visit: Panasonic Official Olympic & Paralympic Website| Panasonic Holdings
About the Panasonic Group
Founded in 1918, and today a global leader in developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, industry, communications, and energy sectors worldwide, the Panasonic Group switched to an operating company system on April 1, 2022 with Panasonic Holdings Corporation serving as a holding company and eight companies positioned under its umbrella. The Group reported consolidated net sales of 8,378.9 billion yen (ca. 59.4 billion Euro) for the year ended March 31, 2023.
To learn more about the Panasonic Group, please visit: https://holdings.panasonic/global/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831059501/en/
Contact information
Tanya Houston, Wildwood Plus, tanya.houston@wildwoodplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom